Trifluoromethanesulfonic Acid

Trifluoromethanesulfonic Acid

SCHEMBL30596404

CCOC(=O)C1C=CC=C1.O=S(=O)([O-])C(F)(F)F.O=S(=O)([O-])C(F)(F)F.[Ru+2]

nearest known ligand 0.34

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.33
KDM4E B2RXH2 3/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
KMT2A Q03164 3/20 0.33
MEN1 O00255 1/20 0.33
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
LMNA P02545 2/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
POLB P06746 1/20 0.32
HTT P42858 2/20 0.31
PKM P14618 1/20 0.31
RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13969445 0.81 ALDH1A1 (0.42) ALDH1A1KDM4EMAPTHPGDKMT2A
Trifluoromethanesulfonic Acid SCHEMBL30596399 0.79 KCNH2 (0.31)
Trifluoromethanesulfonic Acid SCHEMBL30596403 0.76 GPR3 (0.31)
SCHEMBL27669843 0.72
SCHEMBL28408945 0.66 PPM1B (0.40) ALDH1A1KDM4ELMNA
SCHEMBL28923743 0.66 ALDH1A1 (0.42) ALDH1A1KDM4EMAPTHPGDKMT2A
SCHEMBL28409269 0.66 ALDH1A1 (0.42) ALDH1A1KDM4EMAPTHPGDKMT2A
SCHEMBL6316661 0.66 ALDH1A1 (0.42) ALDH1A1KDM4EMAPTHPGDKMT2A
SCHEMBL3000733 0.65 PPM1B (0.38) ALDH1A1KDM4EMAPTHPGDLMNA
Trifluoromethanesulfonic Acid SCHEMBL1138043 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250195463-A1 ORGANOMETALLIC COMPLEX, CONTROLLED-RELEASE MULTI-FUNCTIONAL DRUG, PHARMACEUTICAL COMPOSITION, PROCESSES FOR THE PREPARATION THEREOF AND THEIR USE FACULDADE DE CIENCIAS DA UNIV DE LISBOA (PT) 2025-06-19 US disclosed
EP-4508058-A1 ORGANOMETALLIC COMPLEX, CONTROLLED-RELEASE MULTI-FUNCTIONAL DRUG, PHARMACEUTICAL COMPOSITION, PROCESSES FOR THE PREPARATION THEREOF AND THEIR USE Faculdade de Ciencias da Universidade de Lisboa (PT) 2025-02-19 EP disclosed
WO-2023199134-A1 ORGANOMETALLIC COMPLEX, CONTROLLED-RELEASE MULTI-FUNCTIONAL DRUG, PHARMACEUTICAL COMPOSITION, PROCESSES FOR THE PREPARATION THEREOF AND THEIR USE FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DE LISBOA (PT) 2023-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250195463-A1 ORGANOMETALLIC COMPLEX, CONTROLLED-RELEASE MULTI-FUNCTIONAL DRUG, PHARMACEUTICAL COMPOSITION, PROCESSES FOR THE PREPARATION THEREOF AND THEIR USE SAMM50, CYP4F2, ABCB1 ALDH1A1 1096/4885KDM4E 740/4885MAPT 3470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.